ring was administered either intravenously or orally to male and female rats in order to study the plasma pharmacokinetics of SASP and the plasma profiles of the metabolites.
After intravenous administration SASP was eliminated rapidly from plasma with a half-life (t1/2) of 8min. The volume of distribution (Vdss) of SASP was 0.21/kg and total clearance (CLtot) was 18m1/min x kg. After oral administration, SASP was present in plasma mainly during the first 4 hours. The time for maximal concentration (Tmax) varied for SASP between 1-3 hours, for 14C, corresponding to 5ASA metabolites, between 3-10 hours and for 3H, corresponding to sulfapyridine metabolites, be tween4 -12 hours. The inter-individual variation was considerable. The bioavai lability of SASP was 9% and independent of the dose. The maximal concentr ation(Cmax) and area under the curve (AUC) increased proportionally with the dose. The absorption of SASP was not influenced by fasting overnight. There was a clear sex difference in the metabolism of SASP. The plasma concentration of sulfapyridine metabolites in female rats was twice that in male rats. No hydroxylated metabolites were found in female rat plasma, whereas in the male rats, the hydroxylated sulfapyridine metabolites were the major metabolites. Schroder and Gustavsson (1973)"). In this paper, the plasma kinetics and plasma me tabolites of SASP after a single intravenous or oral administration were studied in the rat. To be able to follow the drug itself as well as metabolites known to be formed by a reductive azo -cleavage", 11) it was decided to incorporate carbon-14 in the carboxylic group and tritium in the phenyl ring in the sulfonamide moiety of SASP.
INTRODUCTION

MATERIALS AND METHODS
Materials
C14CISASP was prepared from 14C-labelled salicylic acid according to the synthetic route shown in scheme 1. The salicylic acid was estrified with methanol and coupled to the diazonium salt obtained from sulfanilic acid. The thus formed compound was after pro tection of the phenolic group activated to give the sulfonyl chloride. The sulfonamide was prepared by coupling of the sulfonyl halide with aminopyridine. Deprotection of the sali cylic acid moiety by double ester hydrolysis under basic conditions and precipitation with acetic acid gave C14CISASP(details of this method will be published elsewhere For detection, a UV detector (Kratos Spectrofow 783) at 360nm was used.
The detection limit in plasma was 1.3pmol/l. The coefficient of variation was ±3% at 75pmol/l and ±9% at 1.5pmol/l. The accuracy was 100% and 99% and the relative re covery 101 and 110% at the two concentration levels, respectively.
Analysis of metabolites
To the plasma samples (100pl), 10pl 1M acetate buffer and 5ul 0-glucuronidase/aryl sulfatase were added and the mixture was incubated at 37C for 3 hours. The detection limits in plasma were for 5ASA 9.3pmol/l, Ac5ASA 3.3pmol/l, SP 5.lp mol /l, SPOH 5.6pmol /l, AcSP 21.9pmol/l and for AcSPOH 14.2pmol/l.
The coefficient of variation was 13.6% for 5ASA and 5.6% for AcSP and below 5% for the other metabolites at a concentration level of 100pM.
Pharmacokinetic analysis
Values of Cmax and Tmax were read directly from concentration data. The areas under the curve were calculated by the trapezoidal method. Pharmacokinetic calculations were performed using the feathering technique with a computer program written in SAS system (SASR Inst. Inc. Box 8000 Cary N.C. USA).
RESULTS
The plasma elimination profiles for 14C and 3H respectively, following the intravenous administration of C14C, 3H7SASP, were similar and fitted to a two compartment model (Fig. 1) . The phase half-life in plasma was 0. 4 hour (about 25 min). The (3-phase show ed a half-life of about 3 hours (Table  I ) . After 16 hours only trace amounts of radio activity remained in plasma. SASP was detectable in plasma by liquid chromatography only during the first 30 min after intravenous administration. The half-life was only 8 min for SASP (Fig. 1) . The plasma clearance for SASP was 17. 9ml/min X kg, which was hours, while the peak for 14C appeared slightly earlier, varying between 3--10 hours. The AUC for 3H was about 50 times and for 14C about 10 times higher than that of SASP .
In female rats the AUC for 3H was twice as high as that in male rats. (Table II and The rats having food ad libitum showed a similar plasma profile to rats starved over night with similar Cmax, Tmax and AUC (Table 1 1 ). In these rats both the blood and the plasma concentrations of radioactivity were determined (Fig. 3) . The concentration in blood followed a similar profile to that in plasma.
The plasma level was initially twice that in blood but the ratio decreased with time indicating some distribution of the meta bolites to the erythrocytes (Table E) .
The metabolites SP, AcSP, SPOH, AcSPOH, 5ASA and Ac5ASA were quantitatively analysed. The metabolic pattern was found to be dependent on sex. The main metabolites in plasma of male rats were SP, SPOH and AcSPOH. In the female rats no hydroxylated metabolites were found in plasma. The major plasma metabolites in female rats were SP and AcSP (Fig. 4) . The total amount of sulfapyridine metabolites in plasma was higher in female rats than in male rats. The Tmax for total sulfapyridine metabolites was 8 hours in both sexes and the Cmax was 95 pM for female rats and 41 pM for male rats after the 50mg dose (Fig. 5 ). Since 14C radioactivity in plasma was low, 5ASA was not possible to quantitate, but after the two highest doses (200 and 500mg/kg) Ac5ASA could be quantitated in male rats with Tmax at 10-12 hours. The maximal plasma concentrations, Cmax, were 5.5 and 13.5pM respectively. and both isotopes disappeared in parallel (Fig. 1) . The total clearance of SASP was almost 10 times that of the radioactivity indicating formation of a primary metabolite of SASP which has a slower elimination than SASP itself. From the chromatographic data and preliminary mass spectrometric data, the unidentified metabolite was tentatively identified as hydroxylated SASP. This compound was not detected in plasma after oral administration.
After an oral dose, both C max and AUC increased proportionally with the dose. However, after the lowest dose, 50mg/kg b.w., which corresponds to a high therapeutic dose, the plasma levels of SASP did not reach the limit of detection, 1.3,umol/l. Plasma concentra tions of SASP comparable with those obtained in clinical use varying between about 10 -100 p mol/1 were reached in the rat at the highest dose , i.e. > 10 times the therapeutic dose, due to the higher clearance of SASP in the rat compared to man. The dominating metabolites in the circulation after oral administration were sulfapyri dine and its metabolites. The amount of 5ASA metabolites in the circulation calculated from the AUC of 14C-radioactivity amounted to about 20% of the amount of SP-metabolites measured as 3H-radioactivity. It is known that 5-aminosalicylic acid is not as well absorbed as sulfapyridine.
The plasma profiles of 3H-radioactivity and total SP-metabolites were similar and excluded the presence of major unknown SP-metabolites.
There were distinct sex-dependent differences in the metabolism ; male rats hydroxylated sulfapyridine, female rats did not. As shown elsewhere") the hydroxylated SP metabolite was further conjugated and rapidly eliminated resulting in lower SP-metabolite levels in plasma in male rats compared to female rats. It is not uncommon with sex differences in rats depending either on sex hormons or a higher oxidating capacity for cytochrome P 450 in male compared to female rats","). No sex difference was observed in dogs"), nei ther have any been reported in man. The metabolic pattern found in male rats was simi lar to that in man while the dog had a simpler metabolic profile 19). Thus in conclusion, SASP has a much shorter half-life in the circulation in rats com pared to man. An unidentified metabolite of SASP with a slower elimination than the drug itself was found after intravenous administration. The bioavailability was similar to man, around 9%. There was a sex-dependent difference in the SP-metabolite pattern in the rat depending on an ability of male rats to hydroxylate SP.
